Literature DB >> 34378174

Consensus Paper: Strengths and Weaknesses of Animal Models of Spinocerebellar Ataxias and Their Clinical Implications.

Jan Cendelin1,2, Marija Cvetanovic3, Mandi Gandelman4, Hirokazu Hirai5,6, Harry T Orr7, Stefan M Pulst4, Michael Strupp8, Filip Tichanek9,10, Jan Tuma9,11, Mario Manto12,13.   

Abstract

Spinocerebellar ataxias (SCAs) represent a large group of hereditary degenerative diseases of the nervous system, in particular the cerebellum, and other systems that manifest with a variety of progressive motor, cognitive, and behavioral deficits with the leading symptom of cerebellar ataxia. SCAs often lead to severe impairments of the patient's functioning, quality of life, and life expectancy. For SCAs, there are no proven effective pharmacotherapies that improve the symptoms or substantially delay disease progress, i.e., disease-modifying therapies. To study SCA pathogenesis and potential therapies, animal models have been widely used and are an essential part of pre-clinical research. They mainly include mice, but also other vertebrates and invertebrates. Each animal model has its strengths and weaknesses arising from model animal species, type of genetic manipulation, and similarity to human diseases. The types of murine and non-murine models of SCAs, their contribution to the investigation of SCA pathogenesis, pathological phenotype, and therapeutic approaches including their advantages and disadvantages are reviewed in this paper. There is a consensus among the panel of experts that (1) animal models represent valuable tools to improve our understanding of SCAs and discover and assess novel therapies for this group of neurological disorders characterized by diverse mechanisms and differential degenerative progressions, (2) thorough phenotypic assessment of individual animal models is required for studies addressing therapeutic approaches, (3) comparative studies are needed to bring pre-clinical research closer to clinical trials, and (4) mouse models complement cellular and invertebrate models which remain limited in terms of clinical translation for complex neurological disorders such as SCAs.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Genetics; Models; Murine; Non-murine; Pathogenesis; Spinocerebellar ataxias; Therapies; Translational

Mesh:

Year:  2021        PMID: 34378174      PMCID: PMC9098367          DOI: 10.1007/s12311-021-01311-1

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.648


  296 in total

1.  Ubiquitous expression of human SCA2 gene under the regulation of the SCA2 self promoter cause specific Purkinje cell degeneration in transgenic mice.

Authors:  Jorge Aguiar; Julio Fernández; Anselmo Aguilar; Yssel Mendoza; María Vázquez; José Suárez; Jorge Berlanga; Silian Cruz; Gerardo Guillén; Luis Herrera; Luis Velázquez; Nieves Santos; Nelson Merino
Journal:  Neurosci Lett       Date:  2005-10-03       Impact factor: 3.046

2.  The P/Q-type voltage-dependent calcium channel as pharmacological target in spinocerebellar ataxia type 6: gabapentin and pregabalin may be of therapeutic benefit.

Authors:  José Gazulla; Mari A Tintoré
Journal:  Med Hypotheses       Date:  2006-08-08       Impact factor: 1.538

3.  Forced activity and environmental enrichment mildly improve manifestation of rapid cerebellar degeneration in mice.

Authors:  Martina Salomova; Filip Tichanek; Dana Jelinkova; Jan Cendelin
Journal:  Behav Brain Res       Date:  2020-12-11       Impact factor: 3.332

Review 4.  Motor Performances of Spontaneous and Genetically Modified Mutants with Cerebellar Atrophy.

Authors:  Robert Lalonde; Catherine Strazielle
Journal:  Cerebellum       Date:  2019-06       Impact factor: 3.847

5.  Early activation of microglia and astrocytes in mouse models of spinocerebellar ataxia type 1.

Authors:  M Cvetanovic; M Ingram; H Orr; P Opal
Journal:  Neuroscience       Date:  2015-01-14       Impact factor: 3.590

6.  In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.

Authors:  Jana Schmidt; Thorsten Schmidt; Matthias Golla; Lisa Lehmann; Jonasz Jeremiasz Weber; Jeannette Hübener-Schmid; Olaf Riess
Journal:  J Neurochem       Date:  2016-07       Impact factor: 5.372

Review 7.  Drosophila melanogaster As a Model Organism to Study RNA Toxicity of Repeat Expansion-Associated Neurodegenerative and Neuromuscular Diseases.

Authors:  Alex C Koon; Ho Yin Edwin Chan
Journal:  Front Cell Neurosci       Date:  2017-03-21       Impact factor: 5.505

8.  The Era of Cerebellar Therapy.

Authors:  Hiroshi Mitoma; Mario Manto
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

Review 9.  From mice to men: lessons from mutant ataxic mice.

Authors:  Jan Cendelin
Journal:  Cerebellum Ataxias       Date:  2014-06-16

10.  Deletion at ITPR1 underlies ataxia in mice and spinocerebellar ataxia 15 in humans.

Authors:  Joyce van de Leemput; Jayanth Chandran; Melanie A Knight; Lynne A Holtzclaw; Sonja Scholz; Mark R Cookson; Henry Houlden; Katrina Gwinn-Hardy; Hon-Chung Fung; Xian Lin; Dena Hernandez; Javier Simon-Sanchez; Nick W Wood; Paola Giunti; Ian Rafferty; John Hardy; Elsdon Storey; R J McKinlay Gardner; Susan M Forrest; Elizabeth M C Fisher; James T Russell; Huaibin Cai; Andrew B Singleton
Journal:  PLoS Genet       Date:  2007-05-16       Impact factor: 5.917

View more
  2 in total

Review 1.  Cholecystokinin Activation of Cholecystokinin 1 Receptors: a Purkinje Cell Neuroprotective Pathway.

Authors:  Harry T Orr
Journal:  Cerebellum       Date:  2022-06-23       Impact factor: 3.847

Review 2.  An insight into the iPSCs-derived two-dimensional culture and three-dimensional organoid models for neurodegenerative disorders.

Authors:  Anushka Bhargava; Ana M Sandoval Castellanos; Sonali Shah; Ke Ning
Journal:  Interface Focus       Date:  2022-08-12       Impact factor: 4.661

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.